BR0015698A - Compositions and methods for treating allergic diseases - Google Patents

Compositions and methods for treating allergic diseases

Info

Publication number
BR0015698A
BR0015698A BR0015698-1A BR0015698A BR0015698A BR 0015698 A BR0015698 A BR 0015698A BR 0015698 A BR0015698 A BR 0015698A BR 0015698 A BR0015698 A BR 0015698A
Authority
BR
Brazil
Prior art keywords
methods
compositions
allergic diseases
treating allergic
relates
Prior art date
Application number
BR0015698-1A
Other languages
Portuguese (pt)
Inventor
Robert Llewellyn Clancy
Gerald Pang
Original Assignee
Probiall Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiall Pty Ltd filed Critical Probiall Pty Ltd
Publication of BR0015698A publication Critical patent/BR0015698A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA TRATAMENTO DE DOENçAS ALéRGICAS". A presente invenção refere-se a métodos de redução dos níveis de IgE e a métodos de tratamento de alergia, mediante administração de uma quantidade terapeuticamente eficaz de uma bactéria probiótica viva ou de uma composição contendo uma bactéria probiótica viva. A presente invenção também refere-se a métodos de identificação de uma bactéria probiótica útil e a composições contendo tal bactéria probiótica."COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALLERGIC DISEASES". The present invention relates to methods of reducing IgE levels and methods of treating allergy by administering a therapeutically effective amount of live probiotic bacteria or a composition containing live probiotic bacteria. The present invention also relates to methods of identifying a useful probiotic bacterium and compositions containing such a probiotic bacterium.

BR0015698-1A 1999-11-19 2000-11-20 Compositions and methods for treating allergic diseases BR0015698A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4158A AUPQ415899A0 (en) 1999-11-19 1999-11-19 Compositions for and methods of treatment of allergic diseases
PCT/AU2000/001414 WO2001037865A1 (en) 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders

Publications (1)

Publication Number Publication Date
BR0015698A true BR0015698A (en) 2002-07-23

Family

ID=3818302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015698-1A BR0015698A (en) 1999-11-19 2000-11-20 Compositions and methods for treating allergic diseases

Country Status (9)

Country Link
EP (1) EP1229930A4 (en)
JP (1) JP2003514869A (en)
KR (1) KR20020084066A (en)
CN (1) CN1391480A (en)
AU (1) AUPQ415899A0 (en)
BR (1) BR0015698A (en)
CA (1) CA2391499A1 (en)
HK (1) HK1049115A1 (en)
WO (1) WO2001037865A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (en) 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
FI110668B (en) 2000-06-20 2003-03-14 Aboatech Ab Oy Use of probiotics for primary prevention of atopic diseases
PE20030283A1 (en) * 2001-07-26 2003-05-01 Alimentary Health Ltd LACTOBACILLUS CASEI STRAINS
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
JP4212838B2 (en) * 2002-06-26 2009-01-21 カルピス株式会社 Antiallergic agent
EP1759597B1 (en) * 2003-03-13 2009-01-21 Kirin Holdings Kabushiki Kaisha Probiotic composition
JP4712289B2 (en) * 2003-08-26 2011-06-29 株式会社エイ・エル・エイ Immune promoting composition
JP4591810B2 (en) * 2003-09-19 2010-12-01 日之出産業株式会社 Nasal composition for controlling hay fever allergic rhinitis
AU2004298384A1 (en) * 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
TWI356680B (en) * 2007-01-05 2012-01-21 Promd Biotech Co Ltd Anti-allergy lactic acid bacteria
CN101328468B (en) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 Antiallergic lactic acid bacteria
CN102657260B (en) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 Antiallergic lactobacillus
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
DK2244734T3 (en) 2008-02-01 2016-08-15 Murdoch Childrens Res Inst PROCEDURE FOR INDUCTION OF TOLERANCE ABOUT AN ALLERGY
KR101827530B1 (en) 2010-08-10 2018-02-09 알.피.쉐러 테크놀러지즈 엘엘씨 Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria
KR101311989B1 (en) * 2010-11-17 2013-09-26 주식회사한국야쿠르트 Products containing Lactobacillus casei HY7211 having immuno-regulatory and immuno-stimulatory functions as effective component
KR102038679B1 (en) * 2018-01-12 2019-10-30 (주)지아이이노베이션 Composition comprising probiotics and ige-binding polypeptide and use thereof
CN111296842B (en) * 2020-02-14 2021-01-05 赵一鸣 Probiotic composition with anti-allergy effect
CN112375722B (en) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 Lactobacillus casei LC-12 for improving allergy, and product and application thereof
WO2024081219A1 (en) 2022-10-14 2024-04-18 Csp Technologies, Inc. Container and method for storing and stabilizing moisture sensitive products
CN117085046A (en) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 Lactobacillus acidophilus LS001 metaplasia and application thereof
CN117887643B (en) * 2024-03-14 2024-06-14 微康益生菌(苏州)股份有限公司 Antiallergic probiotic and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (en) 1978-08-07 1984-11-13 極東脂肪酸株式会社 Allergic reaction inhibitor
JPS5946491B2 (en) 1979-03-14 1984-11-13 極東脂肪酸株式会社 Asthma treatment agent
JPH07265064A (en) 1993-11-23 1995-10-17 Taketoshi Yamada Composition for improving enterobacterial flora
JPH092959A (en) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd Immuno-globulin e antibody production suppressant and antiallergic agent
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
JPH11199495A (en) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk Antiallergic agent using enteric capsule
IT1298918B1 (en) * 1998-02-20 2000-02-07 Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
JP4074006B2 (en) * 1998-06-24 2008-04-09 アサマ化成株式会社 Method for producing IgE antibody production inhibitor and food using the same

Also Published As

Publication number Publication date
CA2391499A1 (en) 2001-05-31
KR20020084066A (en) 2002-11-04
AUPQ415899A0 (en) 1999-12-16
JP2003514869A (en) 2003-04-22
HK1049115A1 (en) 2003-05-02
WO2001037865A1 (en) 2001-05-31
EP1229930A4 (en) 2004-09-22
EP1229930A1 (en) 2002-08-14
CN1391480A (en) 2003-01-15

Similar Documents

Publication Publication Date Title
BR0015698A (en) Compositions and methods for treating allergic diseases
ATE290391T1 (en) ORAL ADMINISTRATION OF LACTOBACILLUS FOR THE TREATMENT AND PREVENTION OF UROGENITAL INFECTIONS
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
BRPI9710372B8 (en) compound, and, pharmaceutical composition.
BR0214705A (en) Composition, use, method for prevention or treatment of neurodegenerative disease, and kit
BR0211888A (en) Materials and Methods for Promoting Nerve Tissue Repair
DE60126980D1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES
GB0223040D0 (en) Therapeutic compounds
ATE416761T1 (en) PREVENTION AND TREATMENT OF INFLAMMATORY AND/OR IMMUNE-MEDIATED BONE LOSS
DK1483366T3 (en) Antimicrobial composition
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
ATE273690T1 (en) COMPOSITION FOR SKIN DISINFECTING
ATE409065T1 (en) INHIBITORS OF 17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
DE602004013146D1 (en) COMPOSITIONS FOR PREVENTING AND TREATING EXPRESSION AND FLUID-LIKE SYMPTOMS CONTAINING CHELINED ZINC
DE69840027D1 (en) SYNTHETIC PEPTIDE CONSTRUCTS FOR THE DETECTION AND TREATMENT OF PARODONTICALLY OBSERVED BY PORPHYROMONAS GINGIVALIS
BR9712141A (en) Application of 1-hyphroxy-2-pyridones to treat skin infections.
BR0316163A (en) Histone Deacetylase Inhibitors for Treatment of Degenerative Eye Diseases
DE59909607D1 (en) TAN-1057 DERIVATIVES
DE60018704D1 (en) BRETYLIUM-CONTAINING COMPOSITIONS AND KITS AND THEIR USE FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
BR9502072A (en) Compound method for the treatment of a medical condition and pharmaceutical composition
AU4568400A (en) Sphingomyelinase inhibitor
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
DE69424679T2 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
BR0108096A (en) Method for maintaining or improving mucin synthesis
BR0317511A (en) Composition comprising reboxetine and a selective cyclooxygenase-2 inhibitor and kit

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PROBIALL PTY LIMITED (AU)

Free format text: ANOTADAS AS ALTERACOES DE SEDE CONFORME A PETICAO NO 020060046936/RJ DE 04/04/2006.

B25A Requested transfer of rights approved

Owner name: ROBERT CLANCY (AU)

Free format text: TRANSFERIDO DE: PROBIALL PTY LIMITED

B25A Requested transfer of rights approved

Owner name: DSM IP ASSETS B.V. (NL)

Free format text: TRANSFERIDO DE: ROBERT CLANCY

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.